https://www.selleckchem.com/products/Mubritinib-TAK-165.html Randomized trials have shown survival gains for patients with metastatic breast cancer (BC) treated with CDK4/6 inhibitors (CDK4/6i) in combination with endocrine agents. It is not unlikely that there may be discrepancies between the generally fit clinical study population and the real-world setting that could affect adherence to treatment guidelines, tolerance to treatment and outcome. Consecutive patients with metastatic or locally advanced and unresectable BC that were treated between July 2017 and January 2020 at Karolinska University Hospital, Stockholm, Sweden and that had received at least one dose of CDK4/6i were included in this retrospective study. The primary endpoint was safety, including toxicity according to CTCAE 5 and rates of treatment interruptions, dose reductions and discontinuations. The secondary endpoint was efficacy based on the treating physicians' assessments in terms of progression free (PFS) and overall survival (OS), as well as the factors associated with patient outcome. Eifficacy of CDK4/6i among patients pretreated with multiple therapy lines is markedly reduced.Objective To examine how changes in health are associated with marital quality over a 20-year period of midlife. Background The health benefit associated with marriage (compared to non-marriage) is well established. Less work has explored how health and changes in a couple's health are associated with the marital relationship. Method We used a sample of continuously married individuals who participated in three waves of the Midlife in the United States study (n = 1768). Multilevel modeling separated within-person changes and between-person differences in the effect of health on marital quality during midlife and older ages. Results Marital support was lower and marital strain was higher for those with worse health relative to peers. Marital quality decreased when health decreased. Effects were particularly strong whe